FDA Approved: * March 28, 2019 Pharm Company: *WATSON LABS INC Category:Blood Pressure
Ambrisentan (U.S. trade name Letairis; E.U. trade name Volibris; India trade name Pulmonext by MSN labs) is a drug indicated for use in the treatment of pulmonary hypertension.
The peptide endothelin constricts muscles in blood vessels, increasing blood pressure. Ambrisentan, which relaxes those muscles, is an endothelin receptor antagonist, and is selective for the type A endothelin receptor (ETA). Ambrisentan significantly improved e...
* May have multiple approval dates, manufacturers, or labelers. 3 Discussions